Skip to content
10-K

Annual Report

X4 Pharmaceuticals, Inc XFOR

0001628280-25-014805

← back to feed
Filed
Mar 26, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 20, 2025 173.66M sh
Capex FY 2024 · Dec 31, 2024 $326K
Capex FY 2024 · Dec 31, 2023 $60K
Capex FY 2024 · Dec 31, 2022 $103K
Cash And Equivalents FY 2024 · Dec 31, 2023 $99.22M
Cash And Equivalents FY 2024 · Dec 31, 2022 $121.72M
Current Liabilities FY 2024 · Dec 31, 2023 $22.86M
Total Liabilities FY 2024 · Dec 31, 2023 $96.16M
Current Assets FY 2024 · Dec 31, 2023 $122.08M
Total Assets FY 2024 · Dec 31, 2023 $147.26M
Shares Diluted restated FY 2024 · Dec 31, 2022 63.53M sh
Operating Cash Flow FY 2024 · Dec 31, 2022 −$77.1M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.52
Eps Basic FY 2024 · Dec 31, 2022 −$1.52
Sga Expense FY 2024 · Dec 31, 2022 $27.02M
Rd Expense FY 2024 · Dec 31, 2022 $61.06M
Net Income FY 2024 · Dec 31, 2022 −$93.87M
Operating Income FY 2024 · Dec 31, 2022 −$87.57M
Cost Of Revenue FY 2024 · Dec 31, 2022 $0
Revenue FY 2024 · Dec 31, 2022 $0
Stockholders Equity FY 2024 · Dec 31, 2021 $64.41M